Literature DB >> 25603329

Proton pump inhibitor-responsive esophageal eosinophilia: a historical perspective on a novel and evolving entity.

Javier Molina-Infante, David A Katzka, Evan S Dellon.   

Abstract

Eosinophilic esophagitis (EoE) is an emerging chronic esophageal disease, first described in 1993, with a steadily increasing incidence and prevalence in western countries. Over the 80's and early 90's, dense esophageal eosinophilia was mostly associated gastroesophageal reflux disease (GERD). For the next 15 years, EoE and GERD were rigidly considered separate entities: Esophageal eosinophilia with pathological acid exposure on pH monitoring or response to proton pump inhibitor (PPI) therapy was GERD, whereas normal pH monitoring or absence of response to PPIs was EoE. Updated guidelines in 2011 described a novel phenotype, proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE), referring to patients who appear to have EoE clinically, but who achieve complete remission after PPI therapy. Currently, PPI-REE must be formally excluded before diagnosing EoE, since 30-40% of patients with suspected EoE are eventually diagnosed with PPI-REE.Interestingly, PPI-REE and EoE remain undistinguishable based on clinical, endoscopic, and histological findings, pH monitoring, and measurement of tissue markers and cytokines related to eosinophilic inflammation.This review article aims to revisit the relatively novel concept of PPI-REE from a historical perspective, given the strong belief that only GERD, as an acid peptic disorder, could respond to the acid suppressing ability of PPI therapy, is becoming outdated. Evolving evidence suggests that PPI-REE is genetically and phenotypically undistinguishable from EoE and PPI therapy alone can almost completely reverse allergic inflammation. As such, PPI-REE might constitute a subphenotype of EoE and PPI therapy may be the first therapeutic step and diet/ steroids may represent step up therapy. Possibly, the term PPI-REE will be soon replaced by PPI-responsive EoE. The mechanism as to why some patients respond to PPI therapy (PPI-REE) while others do not (EoE), remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25603329

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  6 in total

Review 1.  Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches.

Authors:  Bharati Kochar; Evan S Dellon
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-12       Impact factor: 3.869

Review 2.  Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: more similarities than differences.

Authors:  Swathi Eluri; Evan S Dellon
Journal:  Curr Opin Gastroenterol       Date:  2015-07       Impact factor: 3.287

3.  Meta-Analysis-Based Guidance for Dietary Management in Eosinophilic Esophagitis.

Authors:  Alfredo J Lucendo
Journal:  Curr Gastroenterol Rep       Date:  2015-10

Review 4.  Eosinophilic esophagitis: New insights in pathogenesis and therapy.

Authors:  Michele Pier Luca Guarino; Michele Cicala; Jose Behar
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 5.  Eosinophilic esophagitis: From pathophysiology to treatment.

Authors:  Alessandra D'Alessandro; Dario Esposito; Marcella Pesce; Rosario Cuomo; Giovanni Domenico De Palma; Giovanni Sarnelli
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 6.  Eosinophilic esophagitis in children: doubts and future perspectives.

Authors:  Elena Cavalli; Andrea Brusaferro; Elena Sofia Pieri; Rita Cozzali; Edoardo Farinelli; Gian Luigi De' Angelis; Susanna Esposito
Journal:  J Transl Med       Date:  2019-08-09       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.